A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment With Fostair® Pressurized Metered-dose Inhaler (pMDI) 200/12 on Biomarkers of Platelet Adhesion in Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2015
At a glance
- Drugs Beclometasone/formoterol (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Mar 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Apr 2015, according to to ClinicalTrials.gov record.